Evidence map›Paper›PMID 40980451›Full record

ArticleNeuro-oncology advances

Prognostic implication of

Satoshi Nakasu, Shoichi Deguchi, Koichi Mitsuya, Akifumi Notsu, Yoko Nakasu

Abstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Characteristics of [European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Satoshi NakasuDivision of Neurosurgery, Omi Medical Center, Kusatsu, Japan.ORCID https://orcid.org/0000-0001-8719-9806
Shoichi DeguchiDivision of Neurosurgery, Shizuoka Cancer Center, Nagaizumi, Japan.
Koichi MitsuyaDivision of Neurosurgery, Shizuoka Cancer Center, Nagaizumi, Japan.
Akifumi NotsuClinical Research Center, Shizuoka Cancer Center, Nagaizumi, Japan.
Yoko NakasuDepartment of Neurosurgery, Shiga University of Medical Science, Ohtsu, Japan.ORCID https://orcid.org/0000-0002-9852-5707

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Isocitrate dehydrogenase-mutant astrocytomas (A-IDHm) with the homozygous deletion of Methods: The frequency and prognostication of Results: Thirty-three articles with 3739 A-IDHm patients were included. The pooled frequencies of Conclusion: The prognosis of A-IDHm can be stratified by hG and

Indexed as

astrocytomaCDKN2A/Bhomozygous deletionIDH mutationWHO grade

Identifiers

PMID40980451
PMCPMC12448685

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.